跳转至内容
Merck
CN
所有图片(1)

文件

171261

Sigma-Aldrich

AMPK抑制剂,化合物C

InSolution, ≥95%, 10 mM, AMPK Inhibitor

登录查看公司和协议定价

别名:
InSolution AMPK抑制剂,化合物C
经验公式(希尔记法):
C24H25N5O
分子量:
399.49
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

检测方案

≥95% (HPLC)

形式

liquid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
desiccated (hygroscopic)
protect from light

运输

wet ice

储存温度

2-8°C

InChI

1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2

InChI key

XHBVYDAKJHETMP-UHFFFAOYSA-N

一般描述

一种细胞可透过性吡唑并嘧啶化合物,可抑制KDR/VEGFR2、ALK2/BMPR-1、AMPK激酶活性(IC50 = 25.1、148和234.6 nM),而对对ALK5/TGFβR-I、ZAPK、Syk、PKCθ、PKA或JAK3的作用却大大降低或几乎没有。研究表明,可阻断斑马鱼活体胚胎中BMP途径依赖性背腹发育(EC100 = 2.5 µ)和VEGF信号转导依赖性肌间血管形成(EC50 = 5 µM)。通常与 AMPK 激活剂 AICAR(货号 123040)和/或二甲双胍(货号 317240)结合使用,以研究 AMPK 依赖性细胞事件在体外和动物体内的生理反应。

生化/生理作用

主要靶标
AMPK
产物与ATP竞争。
可逆性:是
细胞可渗透性:具有
阻断斑马鱼活体胚胎中BMP途径依赖性背腹发育的EC100 = 2.5 µM;阻断VEGF信号转导依赖性肌间血管形成的EC50 = 5 µM
靶标IC50:抑制KDR/VEGFR2、ALK2/BMPR-1、AMPK激酶活性分别为25.1、148和234.6 nM

包装

用惰性气体包装

警告

毒性:刺激性(B)

外形

提供 10 mM(1 mg/250 µl)的 AMPK 抑制剂,化合物 C(货号171260),溶剂为DMSO

重悬

初次使用后,等分并冷冻(-20°C)。一旦打开,储备溶液在 -20°C 下可稳定保存 3 个月。

其他说明

Hao, J., et al. 2010.ACS Chem.Biol.5, 245.
Kim, E.K., et al. 2004.J. Biol. Chem.279, 19970.
Lee, M., et al. 2003.J. Biol. Chem.278, 39653.
Inoki, K., et al. 2003.Cell115, 577.
Fryer, L.G., 2002.FEBS Lett.531, 189.
Zhou, G., et al. 2001.J. Clin. Invest.108, 1167.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 2

闪点(°F)

closed cup

闪点(°C)

closed cup


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Reetta A E Eriksson et al.
Frontiers in medicine, 9, 1052318-1052318 (2022-12-31)
Gene therapy would greatly benefit from a method to regulate therapeutic gene expression temporally. Riboswitches are small RNA elements that have been studied for their potential use in turning transgene expression on or off by ligand binding. We compared several
Karina Krotova et al.
Human gene therapy, 31(19-20), 1124-1131 (2020-06-05)
Adeno-associated virus (AAV)-based gene therapy is undergoing major expansion into clinical practice, with two treatments currently being granted Food and Drug Administration (FDA) approval. However, the presence of pre-existing neutralizing antibodies (NAB) is one of the significant hurdles for the
David P Santos et al.
Methods in molecular biology (Clifton, N.J.), 1538, 53-66 (2016-12-13)
Human embryonic stem cells (ESCs) are characterized by their unique ability to self-renew indefinitely, as well as to differentiate into any cell type of the human body. Induced pluripotent stem cells (iPSCs) share these salient characteristics with ESCs and can
Yidi Wang et al.
Cells, 11(19) (2022-10-15)
Crouzon syndrome ([OMIM] #123500) caused by FGFR2 mutation is an autosomal dominant syndrome with craniosynostosis, the underlying mechanism of which remains obscure. First, whole exome sequencing was used to screen the possible pathogenic variant in two sporadic patients with Crouzon
Xiaochen Yu et al.
Frontiers in physiology, 13, 817542-817542 (2022-03-19)
Increases in glucose production and decreases in hepatic glycogen storage induce glucose metabolic abnormalities in type 2 diabetes (T2DM). Empagliflozin, a sodium-dependent glucose transporter 2 (SGLT2) inhibitor, is an effective hypoglycemic drug; however, the effects of empagliflozin on hepatic gluconeogenesis

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门